Display options
Cite
Tullos JB, Stoudenmire LL, Pouliot JD. Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Hosp Pharm. 2018;55(1):44-49doi: 10.1177/0018578718817933.
Tullos, J. B., Stoudenmire, L. L., & Pouliot, J. D. (2020). Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Hospital pharmacy, 55(1), 44-49. https://doi.org/10.1177/0018578718817933
Tullos, Jordan Brooke, et al. "Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae." Hospital pharmacy vol. 55,1 (2020): 44-49. doi: https://doi.org/10.1177/0018578718817933
Tullos JB, Stoudenmire LL, Pouliot JD. Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Hosp Pharm. 2020 Feb;55(1):44-49. doi: 10.1177/0018578718817933. Epub 2018 Dec 07. PMID: 31983766; PMCID: PMC6961149.
Copy Download .nbib Format: NLM
Share it on

Hosp Pharm. 2020 Feb;55(1):44-49. doi: 10.1177/0018578718817933. Epub 2018 Dec 07.

Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Hospital pharmacy

Jordan Brooke Tullos, Laura Leigh Stoudenmire, Jonathon David Pouliot

Affiliations

  1. Saint Thomas West Hospital, Nashville, TN, USA.
  2. Lipscomb University, Nashville, TN, USA.

PMID: 31983766 PMCID: PMC6961149 DOI: 10.1177/0018578718817933

[No abstract available.]

© The Author(s) 2018.

Keywords: ESBLs; beta-lactamases; carbapenems; piperacillin-tazobactam; urinary tract infections

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7 - PubMed
  2. Clin Infect Dis. 2012 Jan 15;54(2):167-74 - PubMed
  3. Ann Pharmacother. 2018 May;52(5):484-492 - PubMed
  4. J Antimicrob Chemother. 2012 Dec;67(12):2793-803 - PubMed
  5. Int J Infect Dis. 2014 Dec;29:91-5 - PubMed
  6. PLoS One. 2016 Apr 22;11(4):e0153696 - PubMed
  7. Lancet Infect Dis. 2015 Apr;15(4):475-85 - PubMed
  8. Clin Infect Dis. 2015 May 1;60(9):1319-25 - PubMed
  9. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4159-69 - PubMed
  10. Infect Control Hosp Epidemiol. 2015 Aug;36(8):981-5 - PubMed
  11. Clin Infect Dis. 2017 Apr 1;64(7):972-980 - PubMed

Publication Types